{
    "organizations": [],
    "uuid": "2f4b95052d717ceb18b5c49201e8c99217fd048f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-integragen-presents-positive-data/brief-integragen-presents-positive-data-from-liquid-biopsy-studies-of-mirnas-idUSFWN1RP02E",
    "ord_in_thread": 0,
    "title": "BRIEF-Integragen Presents Positive Data From Liquid Biopsy Studies Of miRNAs",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 12 (Reuters) - INTEGRAGEN SA:\n* INTEGRAGEN PRESENTS POSITIVE DATA FROM LIQUID BIOPSY STUDIES OF COMPANY’S PROPRIETARY MIRNAS DURING 2018 EUROPEAN LUNG CANCER CONFERENCE\n* CO’S PROPRIETARY MIRNA BIOMARKERS PREDICT EGFR TYROSINE KINASE INHIBITOR (EGFR-TKI) TREATMENT RESPONSE\n* MIRNA BIOMARKERS IDENTIFY DRUG RESISTANCE EMERGENCE IN LUNG ADVANCED SQUAMOUS CELL CARCINOMA PATIENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-12T14:09:00.000+03:00",
    "crawled": "2018-04-13T17:42:28.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "integragen",
        "sa",
        "integragen",
        "present",
        "positive",
        "data",
        "liquid",
        "biopsy",
        "study",
        "company",
        "proprietary",
        "mirnas",
        "european",
        "lung",
        "cancer",
        "conference",
        "co",
        "proprietary",
        "mirna",
        "biomarkers",
        "predict",
        "egfr",
        "tyrosine",
        "kinase",
        "inhibitor",
        "treatment",
        "response",
        "mirna",
        "biomarkers",
        "identify",
        "drug",
        "resistance",
        "emergence",
        "lung",
        "advanced",
        "squamous",
        "cell",
        "carcinoma",
        "patient",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}